High-fidelity trapped-ion quantum logic using near-field microwaves

We demonstrate a two-qubit logic gate driven by near-field microwaves in a room-temperature microfabricated ion trap. We measure a gate fidelity of 99.7(1)\%, which is above the minimum threshold required for fault-tolerant quantum computing. The gate is applied directly to $^{43}$Ca$^+$ "atomic clock" qubits (coherence time $T_2^*\approx 50\,\mathrm{s}$) using the microwave magnetic field gradient produced by a trap electrode. We introduce a dynamically-decoupled gate method, which stabilizes the qubits against fluctuating a.c.\ Zeeman shifts and avoids the need to null the microwave field

Magnetic field stabilization system for atomic physics experiments

Atomic physics experiments commonly use millitesla-scale magnetic fields to provide a quantization axis. As atomic transition frequencies depend on the amplitude of this field, many experiments require a stable absolute field. Most setups use electromagnets, which require a power supply stability not usually met by commercially available units. We demonstrate stabilization of a field of 14.6 mT to 4.3 nT rms noise (0.29 ppm), compared to noise of $\gtrsim$ 100 nT without any stabilization. The rms noise is measured using a field-dependent hyperfine transition in a single $^{43}$Ca$^+$ ion held in a Paul trap at the centre of the magnetic field coils. For the $^{43}$Ca$^+$ "atomic clock" qubit transition at 14.6 mT, which depends on the field only in second order, this would yield a projected coherence time of many hours. Our system consists of a feedback loop and a feedforward circuit that control the current through the field coils and could easily be adapted to other field amplitudes, making it suitable for other applications such as neutral atom traps.Comment: 6 pages, 5 figure

Probing Qubit Memory Errors at the Part-per-Million Level

Robust qubit memory is essential for quantum computing, both for near-term devices operating without error correction, and for the long-term goal of a fault-tolerant processor. We directly measure the memory error $\epsilon_m$ for a $^{43}$Ca$^+$ trapped-ion qubit in the small-error regime and find $\epsilon_m<10^{-4}$ for storage times t\lesssim50\,\mbox{ms}. This exceeds gate or measurement times by three orders of magnitude. Using randomized benchmarking, at t=1\,\mbox{ms} we measure $\epsilon_m=1.2(7)\times10^{-6}$, around ten times smaller than that extrapolated from the $T_{2}^{\ast}$ time, and limited by instability of the atomic clock reference used to benchmark the qubit.Comment: 8 pages, 5 figure

Welfare Challenges of Dairy Cows in India Identified Through On-Farm Observations

India has the largest population of dairy cattle in the world at over 48 million animals, yet there has been little formal assessment of their welfare reported. Through observations of dairy cows on 38 farms in Kerala, India, we aimed to investigate the welfare of these animals and the practicality of animal-based assessments within common farming systems. Substantial welfare challenges were identified. All cows were close-tied (less than 1 m length) via a halter that pierced the nasal septum when housed, which was for the entire day (50% of farms) or part thereof. When outside access was available, it was also usually restricted by close-tying, longline tether, or hobbling. Ad libitum water was only available on 22% of farms and food access was also restricted (mean of 4.3 hrs/day). Future work should focus on encouraging dairy farmers in India to improve the welfare of their dairy cattle by ceasing to tie and tether cattle or at least providing tied and tethered cattle with exercise opportunities, unlimited access to drinking water and a readier supply of food (especially quality green forage/fodder); clean housing more frequently; provide strategies to prevent heat stress; breed cattle suited to environmental conditions and with increased resistance to heat stress; carry out welfare assessments more regularly using a validated protocol; rectify the causes of poor welfare. Such changes could substantially improve the welfare of tens of millions of cattle

Illness Beliefs Predict Mortality in Patients with Diabetic Foot Ulcers

Background - Patients’ illness beliefs have been associated with glycaemic control in diabetes and survival in other conditions. Objective - We examined whether illness beliefs independently predicted survival in patients with diabetes and foot ulceration. Methods - Patients (n = 169) were recruited between 2002 and 2007. Data on illness beliefs were collected at baseline. Data on survival were extracted on 1st November 2011. Number of days survived reflected the number of days from date of recruitment to 1st November 2011. Results - Cox regressions examined the predictors of time to death and identified ischemia and identity beliefs (beliefs regarding symptoms associated with foot ulceration) as significant predictors of time to death. Conclusions - Our data indicate that illness beliefs have a significant independent effect on survival in patients with diabetes and foot ulceration. These findings suggest that illness beliefs could improve our understanding of mortality risk in this patient group and could also be the basis for future therapeutic interventions to improve survival

Stiffness-matched biomaterial implants for cell delivery: clinical, intraoperative ultrasound elastography provides a ‘target’ stiffness for hydrogel synthesis in spinal cord injury

Safe hydrogel delivery requires stiffness-matching with host tissues to avoid iatrogenic damage and reduce inflammatory reactions. Hydrogel-encapsulated cell delivery is a promising combinatorial approach to spinal cord injury therapy, but a lack of in vivo clinical spinal cord injury stiffness measurements is a barrier to their use in clinics. We demonstrate that ultrasound elastography – a non-invasive, clinically established tool – can be used to measure spinal cord stiffness intraoperatively in canines with spontaneous spinal cord injury. In line with recent experimental reports, our data show that injured spinal cord has lower stiffness than uninjured cord. We show that the stiffness of hydrogels encapsulating a clinically relevant transplant population (olfactory ensheathing cells) can also be measured by ultrasound elastography, enabling synthesis of hydrogels with comparable stiffness to canine spinal cord injury. We therefore demonstrate proof-of-principle of a novel approach to stiffness-matching hydrogel-olfactory ensheathing cell implants to ‘real-life’ spinal cord injury values; an approach applicable to multiple biomaterial implants for regenerative therapies

The case for investment in tobacco control: lessons from four countries in the Americas

Objective. To synthesize learnings from four national tobacco control investment cases conducted in the Ameri- cas (Colombia, Costa Rica, El Salvador, Suriname) under the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) 2030 project, to describe results and how national health authorities have used the cases, and to discuss implications for the role of investment cases in advancing tobacco control. Methods. We draw on findings from four national investment cases that included 1) a cost-of-illness analysis calculating the health and economic burden of tobacco use, 2) a return-on-investment analysis of implement- ing key tobacco control demand reduction measures, and 3) a subsidiary analysis of one tobacco control topic of national interest (e.g., equity implications of cigarette taxation). Co-authors reported how cases have been used to advance tobacco control. Results. In Colombia, Costa Rica, El Salvador, and Suriname, tobacco use causes social and economic losses equivalent to between 1.0 to 1.8 percent of GDP. Across these countries, implementing WHO FCTC demand reduction measures would save an average of 11 400 lives per year over the next 15 years. Benefits of the mea- sures would far outweigh the costs of implementation and enforcement. Governments are using the cases to advance tobacco control, including to improve tobacco control laws and their enforcement, strengthen tobacco taxation, prioritize tobacco control planning, coordinate a multisectoral response, and engage political leaders. Conclusions. National investment cases can help to strengthen tobacco control in countries, including by increasing public and political support for implementation of the WHO FCTC and by informing effective plan- ning, legislation, coordination and financing

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)